Clinical Trial Update: Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab with or without olaparib in TLS-positive selected resectable soft tissue sarcoma, followed by adjuvant pembrol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Cancer | Phase 2 | Status: WITHDRAWN